Prevnar 13 revenue
Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases. In the first nine months of this year, Prevnar 13 sales grew ~5% YoY (year-over-year) to $4.3 billion from $4.0 billion. US Prevnar 13 sales grew ~2% YoY to $2.6 billion, and international Prevnar 13 sales grew ~12% YoY to $1.7 billion from $1.5 billion. Internationally, Prevnar 13 operations grew ~10% YoY.
In the third quarter, Prevnar 13 revenue grew ~9% YoY to $1.7 billion. US and international Prevnar 13 revenue grew ~12% and ~4% YoY to $1.1 billion and $571.0 million, respectively. Prevnar 13 competes with Merck’s (MRK) Pneumovax 23, whose net revenue fell ~7% YoY to $214.0 million in the third quarter.
Prevnar 13’s and Pneumovax 23’s sales growth could boost Pfizer’s and Merck’s revenue, as well as the Health Care Select Sector SPDR ETF (XLV), of which the stocks comprise ~7.55% and ~6.03%, respectively.
Pfizer to discontinue STRIVE
On December 20, Pfizer announced that it would discontinue its Phase 2b STRIVE trial after a data monitoring committee found that the study was unlikely to reach its pre-defined primary efficacy parameters. STRIVE was evaluating the safety and efficacy of an investigational Staphylococcus aureus multi-antigen vaccine.